MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
197.60%
Cash Ratio
47.04%
Debt to Asset Ratio
275.97%
Unit: Thousand (K) dollars
Assets Breakdown
    • Operating lease assets
    • Short-term investments
    • Other current assets
    • Others
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Liability related to the sale of...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
3,221
8,360
8,482
5,742
Short-term investments
6,652
-
0
7,970
Restricted cash
-
-
0
0
Accounts receivable
318
0
1,253
1,913
Inventories
-
-
0
0
Other current assets
3,339
3,813
2,477
2,807
Total current assets
13,530
12,173
12,212
18,432
Property and equipment, gross
-
-
286
551
Less accumulated depreciation and amortization
-
-
213
404
Property and equipment, net
41
55
73
147
Operating lease assets
6,688
6,879
7,064
10,707
Other assets
765
890
886
881
Total assets
21,024
19,997
20,235
30,167
Accounts payable
824
637
127
318
Accrued compensation
699
629
1,271
2,067
Accrued research and development expenses
57
41
82
342
Deferred revenue
775
684
716
1,011
Liability related to the sale of future revenues - current portion
1,032
715
9,750
9,670
Other current liabilities
3,460
2,939
2,976
4,649
Total current liabilities
6,847
5,645
14,922
18,057
Operating lease liabilities - long-term
8,782
9,076
9,347
15,005
Liability related to the sale of future revenues - long-term
40,506
40,759
32,673
31,976
Other long-term liabilities
1,885
1,829
1,795
1,763
Total liabilities
58,020
57,309
58,737
66,801
Common stock - 0.0001 par value, 500,000 shares authorized as of june 30, 2026 and december 31, 2025 9,443 and 7,324 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
1
1
1
1
Additional paid-in capital
1,993,849
1,988,697
1,983,361
1,981,822
Accumulated other comprehensive income (loss)
-2
0
1
2
Accumulated deficit
-2,030,844
-2,026,010
-2,021,865
-2,018,459
Total stockholders' equity (deficit)
-36,996
-37,312
-38,502
-36,634
Total liabilities and stockholders' equity (deficit)
21,024
19,997
20,235
30,167
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$6,652K (22.73%↑ Y/Y)Other current assets$3,339K (36.34%↑ Y/Y)Cash and cashequivalents$3,221K (-80.94%↓ Y/Y)Accounts receivable$318K Total current assets$13,530K (-45.38%↓ Y/Y)Operating lease assets$6,688K (-39.35%↓ Y/Y)Other assets$765K (-17.48%↓ Y/Y)Property and equipment,net$41K (-76.70%↓ Y/Y)Total assets$21,024K (-43.03%↓ Y/Y)Accumulated deficit-$2,030,844K (-0.83%↓ Y/Y)Accumulated othercomprehensive income (loss)-$2K Total liabilities andstockholders' equity...$21,024K (-43.03%↓ Y/Y)Total stockholders'equity (deficit)-$36,996K (-5.58%↓ Y/Y)Additional paid-in capital$1,993,849K (0.74%↑ Y/Y)Common stock - 0.0001par value, 500,000...$1K (0.00%↑ Y/Y)Total liabilities$58,020K (-19.35%↓ Y/Y)Liability related to thesale of future...$40,506K (0.71%↑ Y/Y)Operating leaseliabilities - long-term$8,782K (-43.07%↓ Y/Y)Total currentliabilities$6,847K (-52.98%↓ Y/Y)Other long-termliabilities$1,885K (8.83%↑ Y/Y)Other currentliabilities$3,460K (-54.90%↓ Y/Y)Liability related to thesale of future...$1,032K Accounts payable$824K (-53.23%↓ Y/Y)Deferred revenue$775K (-51.77%↓ Y/Y)Accrued compensation$699K (-72.61%↓ Y/Y)Accrued research anddevelopment expenses$57K (-94.13%↓ Y/Y)

Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics, Inc. (ATRA)